Faeth Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Anand Parikh
- Full Time Employees
- 29
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1405 Research Blvd Rockville MD United States of America 20850
- IPO Date
- Aug 11, 2014
- CIK
- 0001829802
- Website
- faeththerapeutics.com
- Similar Companies
- Business
- Faeth Therapeutics, Inc. engages in cancer metabolism–driven drug discovery and development, focusing on genotype-guided therapies and precision nutrition to enhance oncologic outcomes. The company operates MetabOS, a data-driven platform that integrates genomic and metabolic data to identify targets and tailor metabolic interventions alongside anti-cancer drugs. Primary activities include discovery and development of metabolicly informed cancer therapeutics, preclinical research, and clinical trial execution across solid tumors; and the exploration of nutritionally optimized regimens as a complement to conventional treatments. Established in 2019, Faeth Therapeutics is headquartered in the United States, with a multi-center clinical program and collaborations aimed at expanding metabolic interventions for cancer care. Core pipeline assets catalogued include FTH-001/003 (Serabelisib + Sapanisertib) targeting PI3K/AKT/mTOR–driven cancers and FTH-002 exploring precise non-essential amino acid restriction for pancreatic and rectal cancers, with development progressing through preclinical and early clinical stages. The company seeks to broaden its metabolic oncology platform through ongoing partnerships, investment support, and expansion of its clinical program, including trials in endometrial and other solid tumors, while pursuing regulatory and commercial opportunities to integrate diet- and metabolism-based strategies into standard cancer care. Faeth emphasizes precision nutrition as a fourth pillar of cancer treatment alongside surgery, radiotherapy, and systemic therapies, aiming to improve efficacy and reduce toxicity across tumor types. Geographic operations span the United States, with partnerships and trials conducted across multiple centers to support its global clinical development agenda. Subsidiaries or parent relationships are not disclosed, and the corporate focus remains on expanding the MetabOS platform and metabolic interventions as a complement to conventional oncology therapeutics.
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Sensei Biotherapeutics (SNSE) Expected to Announce Quarterly Earnings on Friday
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Up 1,973.5% in February
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics Stock Soars 230% After Faeth Deal
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
Sensei Biotherapeutics (NASDAQ:SNSE) vs. Cynata Therapeutics (OTCMKTS:CYYNF) Critical Analysis
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After‑Hours Jump?